Arca Biopharma Inc (NASDAQ:ABIO) focuses on developing genetically targeted therapies for cardiovascular disease. Its lead product candidate, Gencaro, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction. Arca Biopharma Inc (NASDAQ:ABIO) stock performance was 11.34% in last session and finished the day at $2.16. Traded volume was 4,733,955 million shares in the last session and the average volume of the stock remained 1.07 million shares. The beta of the stock remained 3.02. Arca Biopharma Inc (NASDAQ:ABIO) insider ownership is 3.40%.

Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) formerly Nabi Biopharmaceuticals, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota Pharmaceuticals Inc (NASDAQ:BOTA) dropped -11.95 percent to $6.04 yesterday on volume of 462,957.00 million shares. The intra-day range of the stock was $5.90 to $6.89. Biota Pharmaceuticals Inc (NASDAQ:BOTA) has a market capitalization of $211.77 million.

Lpath, Inc. (NASDAQ:LPTN) the industry leader in bioactive lipid-targeted therapeutics, has brought scientists one step closer to finding a potential treatment for traumatic brain injury (TBI) with a recent publication showing that Lpathomab™, a therapeutic antibody, reverses much of the damage caused by trauma to the nervous system.path, Inc. (NASDAQ:LPTN)’s stock on Mar 12, 2014 reported a increase of 1.49% to the closing price of $4.78. Its fifty two weeks range is $3.87 -$6.70. The total market capitalization recorded $ 63.01 million. The overall volume in the last trading session was 174,513 million shares. In its share capital, Lpath, Inc. (NASDAQ:LPTN) has 13.43 million outstanding shares.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) had its price target upped by Noble Financial from $16.00 to $34.00 in a research note issued to investors on Tuesday, American Banking & Market News reports. On Wednesday, shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) dropped -11.92% to close the day at $15.82. Company’s monthly performance is recorded as 116.42%. La Jolla Pharmaceutical Company (NASDAQ:LJPC) quarterly revenue growth is 110.93%.